Results from a phase III trial of patients with metastatic colorectal cancer demonstrated that Erbitux (cetuximab) plus FOLFOX improved outcomes—including progression-free survival, overall survival and best overall response rate—when compared with FOLFOX alone.
Positive results from a phase III trial in advanced colorectal cancer showed that Xilonix-treated patients with advanced disease and multiple symptoms known to inversely correlate with overall survival experienced a 76 percent relative increase in clinical response rate after eight weeks of therapy compared to placebo, at 33 percent vs. 19 percent, respectively (p=.0045).
Amgen and Allergan plc announced results from a phase III study evaluating efficacy and safety of biosimilar ABP 980 compared with trastuzumab in patients with human epidermal growth factor receptor 2-positive early breast cancer.
Niraparib achieved its primary endpoint in a phase III ovarian cancer trial, demonstrating prolonged progression-free survival compared to placebo among patients who are germline BRCA mutation carriers; among patients who are not germline BRCA mutation carriers, but who have homologous recombination deficient tumors as determined by the Myriad myChoice HRD test; and overall in patients who are not germline BRCA mutation carriers.
The U.S. News & World Report rankings of the best cancer hospitals for 2016 brought no great surprises. The top four cancer centers did not change from last year:
Foundation Medicine approached NCI with the idea to make their data useful in the public domain.
Making data broadly available to clinicians and researchers has always been a part of the mission for Foundation Medicine Inc., said Michael Pellini, the company's CEO.
When the Genomic Data Commons opened June 6, the $20 million portal that consolidates NCI's datasets contained genomic information from 14,500 patients.
At a June 21 joint meeting, the NCI Board of Scientific Advisors and the National Cancer Advisory Board approved three concepts and deferred one:
MD Anderson surveyed 450 faculty, trainees and staff Sept. 29 through Nov. 10, 2015, to gather their opinions on campus-carry gun laws. Here's what they said:
